Author

K. E. Muller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:clustering· 2 Organism:mouse· 2 Assay:scRNA-seq· 2

Frequent Co-Authors

D. R. Pattabiraman· 5 shared N. B. Ognjenovic· 4 shared G. A. Mohamed· 3 shared M. Bagheri· 3 shared O. M. Wilkins· 3 shared B. C. Christensen· 2 shared M. A. Mohamed Saleem· 2 shared M. K. Lee· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

D. R. Pattabiraman

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylationchanges with potential therapeutic implications for triple-negative breastcancer

M. Bagheri, M. K. Lee, K. E. Muller, T. W. Miller, D. R. Pattabiraman, B. C. Christensen

This study shows eribulin treatment alters DNA methylation and epigenetic modifier expression in TNBC cells, suggesting potential therapeutic use in triple-negative breast cancer.

bioRxiv · Jun 9, 2023 · PreprintCancer Biology

Pharmacological Induction of mesenchymal-epithelial transition chemosensitizes breast cancer cells and prevents metastatic progression

M. Bagheri, G. A. Mohamed, M. A. Mohamed Saleem, N. B. Ognjenovic, H. Lu, F. W. Kolling, O. M. Wilkins, S. Das, I. S. LaCroix, S. H. Nagaraj, K. E. Muller, S. A. Gerber, T. W. Miller, D. R. Pattabiraman

The paper shows that eribulin induces MET in mesenchymal-like TNBC cells, reducing metastatic potential and increasing sensitivity to other chemotherapeutics.

bioRxiv · Apr 19, 2023 · PreprintCancer Biology

Lineage plasticity enables low-ER luminal tumors to evolve and gain basal-like traits

G. A. Mohamed, S. Mahmood, N. B. Ognjenovic, M. K. Lee, O. M. Wilkins, B. C. Christensen, K. E. Muller, D. R. Pattabiraman

The paper shows low-ER luminal breast tumors can evolve into basal-like traits through lineage plasticity, with SOX10 identified as a potential driver.

bioRxiv · Nov 25, 2022Cancer Biology

Dynamic plasticity within the EMT spectrum, rather than static mesenchymal traits, drives tumor heterogeneity and metastatic progression of breast cancers

M. S. Brown, B. Abdollahi, O. M. Wilkins, P. Chakraborty, N. B. Ognjenovic, K. E. Muller, M. K. Jolly, S. Hassanpour, D. R. Pattabiraman

This study identifies intermediate EMT states in breast cancer and develops a model to quantify their role in tumor heterogeneity and metastasis.

bioRxiv · Mar 17, 2021Cancer Biology

Limiting Self-Renewal of the Basal Compartment Induces Differentiation and Alters Evolution of Mammary Tumors

N. B. Ognjenovic, M. Bagheri, G. A. Mohamed, K. Xu, M. S. Brown, Y. Chen, M. A. Mohamed Saleem, S. H. Nagaraj, K. E. Muller, B. Christensen, D. R. Pattabiraman

This study shows that PKA activation reduces self-renewal of the basal compartment, leading to less aggressive mammary tumors with increased chemotherapy sensitivity.

bioRxiv · Jan 18, 2020Cancer Biology